Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 1/2 8Phase 2 6Phase 3 4

Status

Recruiting 2Not yet recruiting 2Completed 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Follicular 22Lymphoma, Mantle-Cell 18Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Non-Hodgkin 10Lymphoma 6Neoplasms 4Lymphoma, B-Cell 4Leukemia 3Waldenstrom Macroglobulinemia 2Neoplasm, Residual 2Leukemia, Hairy Cell 2Leukemia, B-Cell 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Indolent Non-Hodgkin's Lymphoma 1Indolent Non-Hodgkin Lymphoma 1Disease 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × obinutuzumab × Clear all
NCT06867536 2026-05-15

GLOHRT-01

Huazhong University of Science and Technology

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05848765 2026-05-05

REFRACT

University of Birmingham

Phase 2 Recruiting
284 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT07502872 2026-03-31

TPG

Brown University

Phase 2 Not yet recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02750670 2025-06-22

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

University Health Network, Toronto

Phase 2 Completed
30 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT06549335 2024-10-15

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Ruijin Hospital

Phase 2 Not yet recruiting
66 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

The Lymphoma Academic Research Organisation

Phase 2 Completed
136 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡